KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis.

Lothar Seefried, Serge Ferrari, Dénes Páll, Ombretta Viapiana, Jan Rosa, Jerzy Supronik, Rodina Nestorova Licheva, Joachim Kiefer, Norbert Jeszenői, Károly Horvát-Karajz, Enikő Jókai, István Takács

Osteoporos Int 36(12) 2497-2507

PMID41085683
PMCIDPMC12672812
DOI10.1007/s00198-025-07711-x
发表日期2025-10-14
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 multi panel km;Fig. 2:AI 判定为 other。
摘要

摘要

UNLABELLED: • In women with postmenopausal osteoporosis, proposed denosumab biosimilar RGB-14-P demonstrated equivalent efficacy and pharmacodynamics, and similar immunogenicity and safety to reference denosumab. • RGB-14-P comprehensively replicates the therapeutic benefit of denosumab in a clinical setting. • Denosumab biosimilars, such as RGB-14, have potential to provide lower-cost alternatives to denosumab with comparable efficacy and safety. PURPOSE: To demonstrate the equivalence of the proposed denosumab biosimilar RGB-14-P and the reference denosumab (hereafter denosumab) in women with postmenopausal osteoporosis. METHODS: In this multicentre, double-blind, Phase 3 study (EudraCT 2020-006017-38; NCT05087030), participants were randomised 1:1 to subcutaneous RGB-14-P or denosumab 60 mg every 6 months, on Day 1 and Week 26, with follow-up to Week 52. Primary endpoints were percentage change from baseline (%CfB) in lumbar spine bone mineral density (BMD) at Week 52 and area under the effective curve (AUEC) of %CfB serum C-terminal telopeptide of type 1 collagen (CTX) to Week 26. Secondary endpoints included %CfB in total hip and femoral neck BMD, vertebral and non-vertebral fragility fractures, immunogenicity, and safety to Week 52. RESULTS: Overall, 473 participants were randomised and received study drug (RGB-14-P, n = 242; denosumab, n = 231). Both primary endpoints demonstrated equivalence of RGB-14-P and denosumab. Adjusted mean (95% CI) %CfB in lumbar spine BMD at Week 52 was 4.89 (3.55, 6.24) for RGB-14-P and 4.55 (3.22, 5.87) for denosumab (estimated difference, 0.34; 95% CI, - 0.40, 1.09). Geometric mean ratio in AUEC of %CfB in CTX concentration was 1.01 (95% CI, 0.98, 1.05; P = 0.494). There were no statistical differences in %CfB in total hip and femoral neck BMD. Incidence of vertebral or non-vertebral fragility fractures was comparable between treatments. Anti-drug antibody incidence was < 1% in both arms. Safety was comparable between groups. CONCLUSION: In women with postmenopausal osteoporosis, RGB-14-P demonstrated equivalent efficacy and pharmacodynamics, and similar immunogenicity and safety to denosumab.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Adjusted mean percentage change from baseline (95% CI) in BMD at Week 26 and 52 (full analysis set) a . BMD bone mineral density, CfB change from baseline, CI confidence interval. a Mixed model for repeated measures used to estimate %CfB (95% CI) and P -values
非 KM Figure
Fig. 2Fig. 2 Percentage change from baseline in serum CTX to Week 26 (PD analysis set) a . Error bars represent the SD. ANCOVA analysis of covariance, AUEC area under the effective curve, CfB change from baseline, CI confidence interval, CTX C-terminal telopeptide of type 1 collagen, PD pharmacodynamic, SD standard deviation. a The large SD in the denosumab arm was the result of two outlier patients. b Performed with a mixed-effects model ANCOVA with natural log-transformed AUEC data as the dependent variable and treatment arm, stratification factors (previous use of bisphosphonates [yes/no] and geographical region [Europe, US]), and log of baseline serum CTX as covariates. Log-scale fitted mean and treatment group differences (RGB-14-P – denosumab), together with associated 95% CIs, were back-transformed. The delta method was applied to back transform the geometric mean standard error used for the computation of corresponding 95% CIs
非 KM Figure